Sarepta Therapeutics (NASDAQ:SRPT) Earns Sector Perform Rating from Analysts at Scotiabank

Scotiabank started coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report published on Friday morning,Benzinga reports. The brokerage issued a sector perform rating and a $105.00 target price on the biotechnology company’s stock.

Other analysts have also issued research reports about the company. HC Wainwright reissued a “sell” rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, February 27th. Royal Bank of Canada reduced their price target on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating for the company in a report on Thursday, February 27th. StockNews.com downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft assumed coverage on Sarepta Therapeutics in a report on Tuesday, February 11th. They issued a “hold” rating and a $136.00 price objective for the company. Finally, Needham & Company LLC restated a “buy” rating and set a $202.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $170.41.

Sarepta Therapeutics Stock Down 2.4 %

SRPT stock opened at $103.03 on Friday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The company’s 50 day moving average is $114.11 and its 200 day moving average is $121.27. The stock has a market cap of $10.00 billion, a price-to-earnings ratio of 82.42 and a beta of 0.79. Sarepta Therapeutics has a 1-year low of $99.50 and a 1-year high of $173.25.

Insiders Place Their Bets

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the sale, the director now owns 22,840 shares in the company, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. GF Fund Management CO. LTD. purchased a new stake in shares of Sarepta Therapeutics in the 4th quarter valued at $244,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Sarepta Therapeutics by 11.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 299,301 shares of the biotechnology company’s stock worth $36,392,000 after purchasing an additional 31,098 shares during the period. Woodline Partners LP purchased a new stake in Sarepta Therapeutics during the 4th quarter worth about $5,713,000. Vestal Point Capital LP purchased a new stake in Sarepta Therapeutics during the 4th quarter worth about $30,398,000. Finally, Vident Advisory LLC purchased a new stake in Sarepta Therapeutics during the 4th quarter worth about $357,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.